These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 31443516)

  • 21. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
    von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
    Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
    Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
    Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
    Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
    Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.
    Zhao H; Li D; Zhang B; Qi Y; Diao Y; Zhen Y; Shu X
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29261144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
    Bai X; Ni J; Beretov J; Graham P; Li Y
    Cancer Lett; 2021 Jan; 497():100-111. PubMed ID: 33069769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. STAT3 as a promising chemoresistance biomarker associated with the CD44
    Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
    Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer.
    Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z
    Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
    Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
    BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
    Nedeljković M; Tanić N; Prvanović M; Milovanović Z; Tanić N
    Breast Cancer; 2021 May; 28(3):727-736. PubMed ID: 33420675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker.
    O'Conor CJ; Chen T; González I; Cao D; Peng Y
    Biomark Med; 2018 Jul; 12(7):813-820. PubMed ID: 29902924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple-negative breast cancer-Role of immunology: A systemic review.
    Oner G; Altintas S; Canturk Z; Tjalma W; Verhoeven Y; Van Berckelaer C; Berneman Z; Peeters M; Pauwels P; van Dam PA
    Breast J; 2020 May; 26(5):995-999. PubMed ID: 31797488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
    Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic reprogramming in triple-negative breast cancer.
    Wang Z; Jiang Q; Dong C
    Cancer Biol Med; 2020 Feb; 17(1):44-59. PubMed ID: 32296576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
    Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
    Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.